MEDDDICAL has published a technical guide on AI-generated synthetic health data for pharma professionals, addressing GAN generation, differential privacy, validation, and the regulatory ceiling for RWE Directors, Data Scientists, Medical Affairs, and HEOR leads. https://synthetichealthdata.medddical.com
-- "The conversation around synthetic health data in pharma is frequently either oversold or dismissed," said the team at MEDDDICAL. "Neither position is analytically defensible. There is a precise set of use cases where AI-generated synthetic data outperforms any alternative — rare disease augmentation, cross-border GDPR-compliant data integration, synthetic data in machine learning for medicine and healthcare, and ML training pipelines chief among them. There is an equally precise set of use cases where it should not be used, including primary causal inference for regulatory submissions. The guide draws those boundaries with technical precision."
Debunking the "Made-Up Data" Objection
The guide opens with a direct treatment of the objection most commonly encountered in pharmaceutical settings: that synthetic health data is simply invented and therefore analytically worthless. The firm argues this framing conflates high-fidelity GAN-generated synthetic data — which encodes the statistical structure of real patient populations without containing any real patient's record — with fabricated data.
The guide explains that a synthetic EHR dataset — including synthetic patient records — and high-fidelity synthetic medical data generated by a properly trained and validated generative model encodes genuine epidemiological structure: realistic comorbidity co-occurrence, plausible treatment sequences, age-stratified disease prevalence, and temporal patterns of healthcare utilisation. The privacy protection is structural rather than procedural — the synthetic dataset contains no real records to re-identify.
GAN Architecture and Healthcare-Specific Requirements
The guide provides a detailed treatment of Generative Adversarial Network architectures and their healthcare-specific variants, including medGAN, RGAN, CTGAN, and DP-GAN. Particular attention is paid to temporal modelling requirements for longitudinal EHR data, and to the critical failure mode of mode collapse — a condition where the generator under-represents rare patient subpopulations, which is especially problematic in rare disease contexts.
Differential Privacy: The Mathematical Privacy Guarantee
A substantial section addresses differential privacy, synthetic healthcare data and synthetic healthcare data platform selection criteria, and the synthetic data generation healthcare teams must understand before selecting a synthetic data generator healthcare vendors provide and its implementation through Differentially Private Stochastic Gradient Descent (DP-SGD). The guide provides practical guidance on epsilon (ε) parameter selection, explaining the privacy-utility trade-off at different values and the conditions under which specific ε ranges are appropriate for healthcare applications. The guide states clearly that ε selection requires a documented privacy impact assessment and should not be treated as a purely technical parameter.
Validation Methodology
The guide introduces a three-dimension validation framework requiring assessment of statistical fidelity, analytical utility, and privacy in all validated synthetic datasets. Key metrics are specified with target thresholds: Jensen-Shannon divergence below 0.05 per variable for univariate fidelity; discriminator AUC below 0.60 for multivariate indistinguishability; and the Train-on-Synthetic, Test-on-Real (TSTR) paradigm for utility assessment. The guide emphasises that validation is use-case specific — a dataset validated for ML model training is not automatically validated for RWE support analytics.
Use Case Mapping: Where Synthetic Data Wins and Where It Doesn't
The guide provides explicit use case mapping, covering where a synthetic healthcare database is appropriate, identifying rare disease data augmentation, cross-border GDPR-compliant data sharing, and ML training pipelines as the strongest current use cases. It identifies primary causal inference for regulatory submissions, pharmacovigilance signal detection, and absolute event rate estimation as use cases where synthetic data is currently inappropriate or insufficient.
On cross-border data sharing, the guide notes that the GDPR challenge for multi-country European RWE studies is a structural problem that synthetic data addresses more cleanly than alternative approaches: synthetic data generated at each national site contains no real patient records and can therefore be legally combined across borders without triggering data transfer restrictions.
Regulatory Acceptance: Where the Ceiling Currently Sits
The guide addresses regulatory acceptance with what the firm describes as a precise rather than optimistic framing. Synthetic data healthcare applications are mapped against current regulatory positions with specificity. As of 2026, no major regulatory agency permits AI-generated synthetic health data as the primary evidence source for a regulatory submission. The FDA's most advanced acceptance is in the medical device pathway under CDRH, where synthetic data is explicitly permitted as training and testing data for AI/ML-based medical devices. For drug development, acceptance extends to trial simulation, sensitivity analysis augmentation, and rare disease external control arm contexts.
The guide acknowledges that the regulatory ceiling is not static, citing the EMA's DARWIN EU programme and ongoing FDA engagement with synthetic control arm approaches in rare disease as indicators of an evolving position.
Implementation Framework
The guide concludes with a four-section implementation checklist covering use case definition, data architecture and generation, three-dimension validation, and governance and regulatory documentation — providing a practical framework for pharmaceutical organisations initiating or expanding their use of synthetic health data.
The guide is the fourth publication in MEDDDICAL's RWD Medical Series and the first dedicated to synthetic healthcare data, following guides on phenotype validation in real-world data studies, longitudinal data requirements for RWE, and predictive modelling in healthcare.
About MEDDDICAL
MEDDDICAL is a Pan-European Real-World Evidence advisory service helping pharmaceutical and MedTech organisations navigate the real-world data landscape. MEDDDICAL provides expert guidance on RWE strategy, data source evaluation, vendor selection, and synthetic data strategy across Continental European markets.
Contact: https://medddical.com/contact/
Guide URL: https://synthetichealthdata.medddical.com
Contact Info:
Name: Rainer Muller
Email: Send Email
Organization: MEDDDICAL
Address: Aptos 221 Edificio D2C, Sotogrande, Cadiz 11310, Spain
Website: https://medddical.com
Source: NewsNetwork
Release ID: 89195695
If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.
